Premium
Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease
Author(s) -
Kushleika John,
Checkoway Harvey,
Woods James S.,
Moon JaiDong,
SmithWeller Terri,
Franklin Gary M.,
Swanson Philip D.
Publication year - 1996
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410390315
Subject(s) - selegiline , superoxide dismutase , parkinson's disease , lymphocyte , medicine , disease , immunology , oxidative stress
Abstract Superoxide dismutases (SODs) are metalloenzymes that detoxify superoxide radicals, and occur in cytosolic (Cu,Zn‐SOD) and mitochondrial (Mn‐SOD) forms in multiple tissues, including brain. A neuroprotective effect against oxide stressor exposures may be provided by SOD, although excessive enzyme activity can produce cell injury by formation of hydroxyl radical from hydrogen peroxide. We measured Cu,Zn‐SOD and Mn‐SOD activities in peripheral lymphocytes of 43 newly diagnosed idiopathic Parkinsonapos;s disease (PD) cases and 62 age‐ and sex‐matched controls free of neurodegenerative disorders. Significant excesses of both SOD forms were found among PD cases compared with controls; however, the excesses were found exclusively among PD patients treated with the monoamine oxidase inhibitor selegiline ( L ‐deprenyl). Enzyme‐linked immunosorbent assays (ELI‐ SAs) confirmed that the activity excesses were due to in‐ creased protein rather than more highly reactive enzymes in lymphocytes of PD cases. Our findings clearly indicate the importance of selegiline on measured Cu,Zn‐SOD and Mn‐SOD activity in peripheral lymphocytes. Characterizing a possible therapeutic value of SOD will require longitudinal assessments of SOD in relation to PD progerssion.